MAP Microba Life Sciences Ltd
- 0.165
- 0.0000.00%
Microba Life Sciences Ltd News
Microba's Revenue Climbs 297% in Fiscal Q3
Microba Life Sciences' (ASX:MAP) revenue surged 297% year-on-year to AU$4 million in the third fiscal quarter as the medical diagnostics company launched its world-first pathogen test, according to a
Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5%
Microba Life Sciences (ASX:MAP) secured a AU$6.1 million rebate from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, 2023, according to a W
Microba's Domestic Revenues to Get Boost From Sonic Partnership -- Market Talk
2257 GMT - Microba Life Sciences' domestic revenues will be boosted by the roll-out of its gastrointestinal infectious disease test via Sonic Healthcare, Bell Potter analyst Thomas Wakim says. He poin
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data
Australian shares on Wednesday tracked the gains of their Wall Street peers, which rallied despite the stronger-than-expected US inflation data. The S&P/ASX 200 Index rose 16.90 points, or 0.2%, to 7,
Microba Life Sciences Rise 9% Following Launch of MetaPanel Test With Sonic Healthcare
Microba Life Sciences (ASX:MAP) said the MetaPanel product was launched Wednesday to healthcare professionals. The gastrointestinal pathogen test is available exclusively through Sonic Healthcare (ASX
Miroba Life Sciences Price Target Cut 20% to A$0.35/Share by Bell Potter
Miroba Life Sciences Price Target Cut 20% to A$0.35/Share by Bell Potter
Microbia Life Sciences Offers Compelling Long-Term Opportunity -- Market Talk
0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. Initiati
Microba Life Sciences Started With A$0.35/Share Target Price by Morgans>MAP.AU
Microba Life Sciences Started With A$0.35/Share Target Price by Morgans>MAP.AU
Microba Life Sciences Validates Safety, Tolerability of Inflammatory Bowel Disease Therapy in Phase One Trial
Microba Life Sciences (ASX:MAP) validated the safety and tolerability of the inflammatory bowel disease therapy MAP 315 in healthy volunteers following results from a recent phase one trial. The study
Microba Life Sciences Completes Acquisition of UK Microbiome Testing Company; Shares Slide 5%
Microba Life Sciences (ASX:MAP) on Tuesday completed the acquisition of UK-registered microbiome testing company Invivo Clinical. Deal completion followed the approval of all resolutions related to th
Microba Life Sciences Signs Research Agreement With IFF Subsidiary to Develop Allergy Treatments
Microba Life Sciences (ASX:MAP) signed a research agreement with International N&H Denmark ApS, a wholly-owned subsidiary of IFF, the precision microbiome firm said on Monday. The parties will develop
Microba Life Sciences' Domestica, International Personal Testing Revenue Rises in Fiscal Q1
Microba Life Sciences' (ASX:MAP) revenue for its domestic personal testing grew 62% in the first fiscal quarter, while revenue from its international personal testing revenue jumped 72%, a Thursday fi
Microba Life Sciences to Acquire Invivo Clinical
Microba Life Sciences (ASX:MAP) signed a share purchase agreement for the acquisition of all the issued share capital in the UK-registered company, Invivo Clinical, the precision microbiome firm said
Microba Life Sciences Price Target Cut 8.3% to A$0.55/Share by Bell Potter
Microba Life Sciences Price Target Cut 8.3% to A$0.55/Share by Bell Potter
Microba Life Sciences (ASX:MAP) Shareholders Have Endured a 22% Loss From Investing in the Stock a Year Ago
Companies Like Microba Life Sciences (ASX:MAP) Are In A Position To Invest In Growth
Analysis
Price Target
No Data
